TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34930354

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 7

Group type: COMPARATOR
Intervention: CT
Number of subjects: 7
Study: 34930356

Group type: EXPERIMENTAL
Intervention: High serum choline concentrations (median 9.51 μg/mL)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Quartiles 2-4 (serum choline ≥ 4.00 μg/mL)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Non-drinking status
Number of subjects: 558

Group type: COMPARATOR
Intervention: Low serum choline concentrations (median 7.80 μg/mL)
Number of subjects: 558
Study: 34930368

Group type: EXPERIMENTAL
Intervention: Proton beam radiotherapy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Intensity modulated photon radiation techniques (standard arm)
Number of subjects: 326
Study: 34930401

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Plain balloon angioplasty (PBA)
Number of subjects: 170
Study: 34930418

Group type: EXPERIMENTAL
Intervention: XR-based BLS training
Number of subjects: 154

Group type: COMPARATOR
Intervention: Conventional CPR training video
Number of subjects: 154
Study: 34930421

Group type: EXPERIMENTAL
Intervention: 40Hz transcranial alternating current stimulation (tACS) administered 1 h daily for 2 or 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40Hz transcranial alternating current stimulation (tACS)
Number of subjects: 15
Study: 34930428

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic < 140 mmHg), glycemic control (target 6.1-7.8 mmol/L for non-diabetics and 7.8-10.0 mmol/L for diabetics), anti-pyrexia treatment (target body temperature ≤ 37.5 °C), reversal of anticoagulation (target INR < 1.5 within 1 hour)
Number of subjects: 8360

Group type: COMPARATOR
Intervention: Standard care (control phase)
Number of subjects: 8360
Study: 34930440

Group type: EXPERIMENTAL
Intervention: Positive suggestion intervention by ICU doulas
Number of subjects: 43
Study: 34930487

Group type: EXPERIMENTAL
Intervention: Pharmacist interventions
Number of subjects: 141
Study: 34930497

Group type: EXPERIMENTAL
Intervention: Facilitator coaching style
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Formal authority coaching style
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Delegator or personal model coaching styles
Number of subjects: 137
Study: 34930500

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy including online training videos, customized algorithm, technology for workflow efficiency, implementation training, clinic support, coaching, and written protocols.
Number of subjects: 5
Study: 34930717

Group type: EXPERIMENTAL
Intervention: Mild PVR
Number of subjects: 1128

Group type: COMPARATOR
Intervention: None/Trace PVR
Number of subjects: 1128
Study: 34930734

Group type: EXPERIMENTAL
Intervention: Thoracoscopic surgery with additional treatment after bulla resection (specific details not provided).
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Various surgical options (specific details not provided).
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Adverse outcomes correlated with various treatments (specific details not provided).
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Feasibility of treatment methods (specific details not provided).
Number of subjects: 450
Study: 34930741

Group type: EXPERIMENTAL
Intervention: Reperfusion treatment at secondary hospitals
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy at secondary hospitals
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention at secondary hospitals
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy timing
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Coronary angiography timing
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Onset-to-first-medical-contact time at secondary hospitals
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Adjusted in-hospital mortality
Number of subjects: 5063

Group type: COMPARATOR
Intervention: In-hospital death or treatment withdrawal
Number of subjects: 5063
Study: 34930747

Group type: EXPERIMENTAL
Intervention: Psychological distress measured using the Clinical Outcomes in Routine Evaluation-Outcome Measure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measured by the EuroQol five-dimension-three-level
Number of subjects: 0
Study: 34930871

Group type: EXPERIMENTAL
Intervention: Hypocaloric nutrition with high protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased protein intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 0
Study: 34930928

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (three batches) administered as dose 1, followed by MVA-BN-Filo (one batch) as dose 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (intermediate dose: 2×10^11 viral particles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (different dose levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo (as dose 2)
Number of subjects: 0
Study: 34931202

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP) high titer (≥1:320)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 168
Study: 34931603

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment for 3 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment
Number of subjects: 259
Study: 34931696

Group type: EXPERIMENTAL
Intervention: Dietary advice (DA)
Number of subjects: 10284

Group type: EXPERIMENTAL
Intervention: Dietary advice (DA) plus oral nutritional supplements (ONS)
Number of subjects: 10284

Group type: COMPARATOR
Intervention: Dietary advice (DA) plus ONS
Number of subjects: 10284

Group type: COMPARATOR
Intervention: Dietary advice (DA) versus ONS
Number of subjects: 10284

Group type: COMPARATOR
Intervention: Dietary advice (DA) versus DA plus ONS
Number of subjects: 10284

Group type: EXPERIMENTAL
Intervention: Dietary advice (DA) plus ONS versus no advice or ONS
Number of subjects: 10284
Study: 34931880

Group type: EXPERIMENTAL
Intervention: Three different immunoglobulin administration modalities
Number of subjects: 0
Study: 34931986

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 320

Group type: COMPARATOR
Intervention: CT
Number of subjects: 320
Study: 34931994

Group type: EXPERIMENTAL
Intervention: Moderate consumption of lean red meat 3 times per week for 10 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Meat alternatives 3 times per week for 10 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Questionnaires assessing well-being and mental health every 2 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Body composition, physical function, and blood parameters assessed at allocation
Number of subjects: 80
Study: 34932001

Group type: EXPERIMENTAL
Intervention: Pharmacological recognition survey completed by community pharmacies (CPs)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: New integrated IT platform for medication reconciliation
Number of subjects: 134
Study: 34932005

Group type: EXPERIMENTAL
Intervention: Adapted version of the active app with insightful notifications, progress visualization, and access to researcher contact details
Number of subjects: 140

Group type: COMPARATOR
Intervention: Active app as usual
Number of subjects: 140
Study: 34932165

Group type: EXPERIMENTAL
Intervention: Biventricular CMR-FT analysis for 2-dimensional systolic and diastolic measures
Number of subjects: 125
Study: 34932284

Group type: EXPERIMENTAL
Intervention: AboBoNT-A (Dysport) injections, mean doses 909-934 U between cycles 1 and 4
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: OnaBoNT-A (Botox) injections
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: IncoBoNT-A (Xeomin) injections
Number of subjects: 168
Study: 34932394

Group type: EXPERIMENTAL
Intervention: Balstilimab (3 mg/kg every 2 weeks) and Zalifrelimab (1 mg/kg every 6 weeks)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Balstilimab and Zalifrelimab
Number of subjects: 155
Study: 34932560

Group type: EXPERIMENTAL
Intervention: mOPV2
Number of subjects: 0
Study: 34932580

Group type: EXPERIMENTAL
Intervention: Multidisciplinary telemedicine intervention program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard medical care only
Number of subjects: 76
Study: 34932793

Group type: EXPERIMENTAL
Intervention: Atezolizumab alone (cohort A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus azacitidine (cohort B)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus azacitidine (cohort C)
Number of subjects: 46
Study: 34932828

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34932836

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (haemoglobin threshold 7.0 g/dL to 8.0 g/dL)
Number of subjects: 21433

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (haemoglobin threshold 9.0 g/dL to 10.0 g/dL)
Number of subjects: 21433

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 21433

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 21433
Study: 34932887

Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss intervention
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Childhood physical abuse
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Binge eating severity
Number of subjects: 431
Study: 34932984

Group type: EXPERIMENTAL
Intervention: SAR441255
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual GLP-1/GCG receptor agonist
Number of subjects: 0
Study: 34932991

Group type: COMPARATOR
Intervention: High-volume hospitals (>15 cases)
Number of subjects: 516
Study: 34933328

Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel)
Number of subjects: 128
Study: 34933330

Group type: EXPERIMENTAL
Intervention: Idasanutlin
Number of subjects: 27
Study: 34933419

Group type: EXPERIMENTAL
Intervention: Nonmicroradical resection (0-mm margin)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Resection margin ≤1-mm without direct invasion
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (microradical resections)
Number of subjects: 276
Study: 34933701

Group type: EXPERIMENTAL
Intervention: Triclosan 0.5% followed by 70% alcoholic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triclosan 0.5% by scrubbing
Number of subjects: 0
Study: 34933824

Group type: EXPERIMENTAL
Intervention: CRP measures collected at antimicrobial treatment start (V1), seven to 10 days later (V2), and two weeks after treatment end (V3).
Number of subjects: 982
Study: 34933855

Group type: EXPERIMENTAL
Intervention: AcuPebble_SA100
Number of subjects: 150
Study: 34933897

Group type: EXPERIMENTAL
Intervention: OCTA (Angiovue; Optovue, Fremont, California, USA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: OCTA
Number of subjects: 88
Study: 34933964

Group type: EXPERIMENTAL
Intervention: IL-6 levels above median
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: IL-6 levels in the highest quartile
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Acute and sustained elevation of IL-6 measured 4 months after STEMI
Number of subjects: 269
Study: 34933965

Group type: EXPERIMENTAL
Intervention: sST2 concentrations at baseline
Number of subjects: 123
Study: 34934034

Group type: EXPERIMENTAL
Intervention: Antivascular endothelial growth factor therapy
Number of subjects: 2433
Study: 34934447

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) followed by convalescent plasma (CVP) transfusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard treatment according to hospital protocols
Number of subjects: 38
Study: 34934801

Group type: EXPERIMENTAL
Intervention: DRP3™ screen (a brief screening tool for H+D in dementia)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DRP3™ screen
Number of subjects: 0
Study: 34934864

Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg intravenously every 4 weeks) + Stereotactic Radiosurgery (SRS)
Number of subjects: 12
Study: 34934978

Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate (VLC) diet for 16 weeks
Number of subjects: 29
Study: 34934987

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg) twice weekly + placebo daily for 6 months
Number of subjects: 9

Group type: COMPARATOR
Intervention: Norethindrone acetate (5 mg/day) + placebo twice weekly
Number of subjects: 9
Study: 34935127

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (betamethasone or dexamethasone)
Number of subjects: 942

Group type: COMPARATOR
Intervention: Usual care (placebo or no treatment)
Number of subjects: 942
Study: 34935175

Group type: EXPERIMENTAL
Intervention: Stage IV periodontitis
Number of subjects: 214

Group type: COMPARATOR
Intervention: Stage I-III periodontitis
Number of subjects: 214
Study: 34935409

Group type: EXPERIMENTAL
Intervention: Acute ischemic stroke/transient ischemic attack (AIS/TIA)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage (ICH)
Number of subjects: 734
Study: 34935412

Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) volume measured with cardiac magnetic resonance
Number of subjects: 105
Study: 34935483

Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T therapy with ≥ grade 2 CRS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T therapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bridging hematopoietic stem cell transplantation
Number of subjects: 22
Study: 34935687

Group type: EXPERIMENTAL
Intervention: 100 mL 4% gelatin intravenous boluses (five sequential boluses)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 200 mL fluid challenge (FC)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fluid administration
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Baseline Ea
Number of subjects: 47
Study: 34935913

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine (two doses of Pfizer-BioNTech)
Number of subjects: 129
Study: 34936055

Group type: EXPERIMENTAL
Intervention: Oral BI 425809 25 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: IV microtracer infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tablet-form BI 425809
Number of subjects: 6
Study: 34936689

Group type: COMPARATOR
Intervention: Multimodal assessment tools (symptom, cognitive, visual, motor) using digital methods
Number of subjects: 200
Study: 34936697

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus lenalidomide (GALEN combination)
Number of subjects: 100
Study: 34936849

Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor Therapy
Number of subjects: 0
Study: 34937189

Group type: EXPERIMENTAL
Intervention: Piperacillin-Tazobactam continuous infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Piperacillin-Tazobactam intermittent bolus, extended infusion, and continuous infusion methods
Number of subjects: 26
Study: 34937556

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 146

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 146
Study: 34937583

Group type: EXPERIMENTAL
Intervention: Legume intake
Number of subjects: 2247

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2247
Study: 34937709

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 235
Study: 34937720

Group type: EXPERIMENTAL
Intervention: Stratified treatment based on prognostic factors
Number of subjects: 1000
Study: 34937722

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention using a clinical decision support system based on behavioural economic and user-centred design principles.
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 184
Study: 34937724

Group type: EXPERIMENTAL
Intervention: Follow-up care every 4 weeks in long interdialytic interval (LIDI) for pre-dialysis and post-dialysis serum potassium measurements.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Follow-up visit in the short interdialytic interval (SIDI) during the first week.
Number of subjects: 600
Study: 34937781

Group type: EXPERIMENTAL
Intervention: High CSF Aβ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher CSF Aβ
Number of subjects: 0
Study: 34937789

Group type: EXPERIMENTAL
Intervention: Modified Erasmus GBS Outcome Score (mEGOS) at entry
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Modified Erasmus GBS Outcome Score (mEGOS) at week 1
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Recalibrated mEGOS for Europe/North America (mEGOS-Eu/NA)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Individual predictive factors of mEGOS
Number of subjects: 1500
Study: 34937871

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO MONO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (COMBO)
Number of subjects: 32
Study: 34938226

Group type: EXPERIMENTAL
Intervention: Mindfulness program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no mindfulness program)
Number of subjects: 0
Study: 34938285

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H1N1pdm09 vaccine (2009)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Seasonal vaccination (2010/11-2013/14)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Current vaccination (2013/14)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Two- and three-year gap before vaccination (2013/14)
Number of subjects: 55
Study: 34938664

Group type: EXPERIMENTAL
Intervention: Venetoclax 800 mg/day
Number of subjects: 17
Study: 34938699

Group type: EXPERIMENTAL
Intervention: Intervention details are not available
Number of subjects: 0
Study: 34938780

Group type: EXPERIMENTAL
Intervention: Home-Based Exercise and Cognitive Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34938862

Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal transsphenoidal surgery
Number of subjects: 44
Study: 34938959

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 309
Study: 34939008

Group type: EXPERIMENTAL
Intervention: HDx therapy (medium cut-off dialyzer) for 12 weeks after a 2-week baseline observation period of conventional high-flux HD
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HDx therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dynamic PROM assessment
Number of subjects: 28
Study: 34939013

Group type: EXPERIMENTAL
Intervention: Marine n-3 PUFA (2.6 g daily for 44 weeks)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 132
Study: 34939109

Group type: COMPARATOR
Intervention: No ACL reconstruction (no ACLR)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Post-ACLR
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Baseline general self-efficacy
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Baseline knee function
Number of subjects: 275
Study: 34939173

Group type: EXPERIMENTAL
Intervention: FDG PET/CT imaging
Number of subjects: 104
Study: 34939444

Group type: EXPERIMENTAL
Intervention: Yoga practice combined with patient education (PE) for at-home practice, 12 weeks duration, including two 6-week periods: P1 with one 90-minutes supervised yoga-PE session/week and 15-minutes daily at-home yoga, P2 with daily autonomous at-home yoga sessions.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Yoga practice combined with patient education (PE) for at-home practice
Number of subjects: 24
Study: 34939972

Group type: EXPERIMENTAL
Intervention: Electrical stimuli-based quantitative sensory testing (QST)
Number of subjects: 72
Study: 34939987

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy initiation among AYALWH older than 10 years
Number of subjects: 5316

Group type: EXPERIMENTAL
Intervention: Facilities with youth-friendly services (YFS) and trained providers
Number of subjects: 5316

Group type: EXPERIMENTAL
Intervention: Overall viral suppression among AYALWH
Number of subjects: 5316
Study: 34941047

Group type: EXPERIMENTAL
Intervention: Combined treatment with anlotinib, irinotecan, and vincristine
Number of subjects: 35
Study: 34941067

Group type: EXPERIMENTAL
Intervention: Leuprorelin 1.88 to 3.75 mg subcutaneously once every 4 weeks for 96 weeks
Number of subjects: 307
Study: 34941429

Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulation, details on dosage and duration not available
Number of subjects: 0
Study: 34941552

Group type: EXPERIMENTAL
Intervention: Comprehensive Research Information System (CRIS)
Number of subjects: 0
Study: 34941904

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional monitoring (CM)
Number of subjects: 89
Study: 34941929

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 34941996

Group type: EXPERIMENTAL
Intervention: Glofitamab (5 µg-25 mg) after single-dose obinutuzumab pretreatment (1000 mg) 7 days prior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glofitamab (5 µg-25 mg)
Number of subjects: 0
Study: 34942053

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1703
Study: 34942138

Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate (2.5-9.0 g/night)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate
Number of subjects: 154
Study: 34942337

Group type: EXPERIMENTAL
Intervention: US-LRA group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 34942516

Group type: EXPERIMENTAL
Intervention: Anodal stimulation (target network: DMN in AD, SN in bvFTD)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cathodal stimulation (target network: SN in AD, DMN in bvFTD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Functional connectivity
Number of subjects: 45

Group type: COMPARATOR
Intervention: Perfusion measures
Number of subjects: 45

Group type: COMPARATOR
Intervention: Interaction between DMN and SN functional connectivity changes
Number of subjects: 45
Study: 34944886

Group type: EXPERIMENTAL
Intervention: Yeast-derived beta glucan (BG) combined with anti-GD2 murine monoclonal antibody 3F8, intravenous 3F8 at a fixed dose of 10 mg/m².
Number of subjects: 0
Study: 34945081

Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (STP)
Number of subjects: 0